Humacyte (NASDAQ:HUMA – Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Humacyte to post earnings of ($0.10) per share and revenue of $1.4640 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.
Humacyte (NASDAQ:HUMA – Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.35 million. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. On average, analysts expect Humacyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Humacyte Stock Down 4.8%
Humacyte stock traded down $0.04 during mid-day trading on Tuesday, hitting $0.88. The company had a trading volume of 2,102,128 shares, compared to its average volume of 6,233,893. The stock has a market cap of $195.38 million, a price-to-earnings ratio of -4.40 and a beta of 2.31. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.93. The company has a quick ratio of 2.95, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. The business has a fifty day moving average of $0.88 and a 200 day moving average of $1.10.
Hedge Funds Weigh In On Humacyte
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on HUMA. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. BTIG Research reaffirmed a “buy” rating and issued a $3.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Benchmark cut their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and a consensus target price of $7.71.
Check Out Our Latest Research Report on Humacyte
Humacyte Company Profile
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Read More
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
